ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders
about
Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognitionSelectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brainEfficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover studyNegative affective states and cognitive impairments in nicotine dependenceNicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disordersABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice.Mouse models for studying genetic influences on factors determining smoking cessation success in humans.BRAIN MYELINATION IN PREVALENT NEUROPSYCHIATRIC DEVELOPMENTAL DISORDERS: PRIMARY AND COMORBID ADDICTION.High throughput electrophysiology with Xenopus oocytesPrefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signalingProgress and challenges in the study of α6-containing nicotinic acetylcholine receptors.Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists.Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats.Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study.An update on pharmacological approaches to neurodegenerative diseases.Cholinergic control over attention in rats prone to attribute incentive salience to reward cues.Donepezil for Alzheimer's disease.Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trialsActivation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors.The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions.Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder.Pozanicline for the treatment of attention-deficit/hyperactivity disorder.Progress in the development of new drugs in Alzheimer's disease.The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.Mapping of the interaction sites of galanthamine: a quantitative analysis through pairwise potentials and quantum chemistry.
P2860
Q24614080-0808F8B9-4A1F-454A-A02D-8034A694DBE5Q24645468-65860475-0D5D-4EC0-873B-1ED682869C5BQ28243031-63BD375E-DCA3-454F-8375-9D2A2C4D9578Q30371220-C889F11C-6E97-4FAC-94F1-6B7BAC2AFE6DQ30372351-B2883B5C-515C-4E1A-9FD4-B5AC81CBCB82Q30386914-7CC1483F-1682-4C0A-BD57-1D1DFABC7D51Q30432964-ACAC67E4-1F15-4527-A050-740D40CDBF03Q30493846-57D6CEE9-82C3-4F1F-8131-2AD9B62FFFCAQ33400496-D016D640-7828-47C3-9CC0-1453BAB2F2B1Q33830056-23483CC9-33B8-4528-B714-0B293234C246Q33954007-668D94B4-835E-45F6-9196-B62378EFAD97Q34215376-DE9BE4AE-6A5F-47C3-B072-4FB538D00133Q34266602-34ADA71B-128B-46E3-BAA6-168AC603FB83Q35831671-90B8347C-8545-4DA8-9128-A0150421623FQ36677402-223A807E-46AF-4F36-A852-018229DEBEC6Q36949159-EF756138-9CFD-45E5-8BBC-98532E9DD16FQ36972671-60E05E24-5CD9-43EF-A731-4503FFED5EB2Q37134091-DE73C0AA-76C8-4819-8531-20C6F3818EC5Q37707730-DF504388-54B5-428F-A10C-81493F1AE443Q38090678-A7BE91B7-B01A-43DF-930E-9580B737720BQ38223307-82996B0B-E0FB-498C-8910-6A9EDF04F180Q38246678-E7D4A16D-6C6C-4375-AAD4-579F961C5CF5Q39789745-2E632354-B3FA-4C78-946E-DFEC05E7FCBCQ48375752-E1AB8E57-30C6-4ABB-A47D-98B3364B7991Q53332785-AD899626-670D-41D1-9987-1893CF05B8D7
P2860
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders
description
2004 nî lūn-bûn
@nan
2004 թուականին հրատարակուած գիտական յօդուած
@hyw
2004 թվականին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
ABT-089: pharmacological prope ...... eatment of cognitive disorders
@ast
ABT-089: pharmacological prope ...... eatment of cognitive disorders
@en
ABT-089: pharmacological prope ...... eatment of cognitive disorders
@nl
type
label
ABT-089: pharmacological prope ...... eatment of cognitive disorders
@ast
ABT-089: pharmacological prope ...... eatment of cognitive disorders
@en
ABT-089: pharmacological prope ...... eatment of cognitive disorders
@nl
prefLabel
ABT-089: pharmacological prope ...... eatment of cognitive disorders
@ast
ABT-089: pharmacological prope ...... eatment of cognitive disorders
@en
ABT-089: pharmacological prope ...... eatment of cognitive disorders
@nl
P2093
P1476
ABT-089: pharmacological prope ...... eatment of cognitive disorders
@en
P2093
Bryan F Cox
Clark A Briggs
David J Anderson
Diana L Donnelly-Roberts
Gary A Gintant
Glenn A Reinhart
James P Sullivan
Lee C Preusser
Lynne E Rueter
Mark A Osinski
P304
P356
10.1111/J.1527-3458.2004.TB00011.X
P407
P577
2004-01-01T00:00:00Z